CJC-1295 (No DAC) — Modified GRF 1-29

Background

CJC-1295 No DAC (also called Modified GRF 1-29 or Mod GRF 1-29) is a tetrasubstituted analogue of GHRH(1-29) with amino-acid substitutions (D-Ala at position 2, Gln at position 8, Ala at position 15, Leu at position 27) conferring resistance to enzymatic degradation. The 'No DAC' designation distinguishes it from the original CJC-1295, which included a Drug Affinity Complex (DAC) maleimide moiety for albumin binding and extended half-life.

Without the DAC moiety, the peptide has a short plasma half-life (~30 minutes) and produces a brief, physiological GH pulse.

Mechanism

Binds the pituitary GHRH receptor, producing a clean, short pulse of GH release. Frequently combined with a ghrelin-receptor agonist (Ipamorelin) for synergistic GH release that better mimics natural pulsatile patterns.

What is proven

The pharmacology of GHRH-mediated GH release and the synergy between GHRH analogues and GHRPs is established in human pharmacology studies. Combined GHRH-analog + GHRP administration produces greater GH responses than either alone.

Original DAC-bearing CJC-1295 reached Phase 2 trials (sponsor: ConjuChem) but development was discontinued.

What is NOT proven

No completed Phase 3 trials in humans for any indication. Long-term safety and body-composition or anti-ageing efficacy in healthy adults rests on pharmacology, not registrational outcomes.

Open research questions

Optimal pulse frequency and timing relative to sleep architecture; long-term IGF-1 elevation safety; whether 'pulsatile mimicry' confers a real advantage over continuous low-level GH/IGF-1 elevation.

Regulatory status

Not approved by any major regulator.

All Proteus® compounds are sold strictly for in-vitro research. Nothing on this page is medical advice, a treatment claim, or a recommendation for human use. Where compounds are licensed medicines in any jurisdiction, that approval applies to the licensed product supplied through a regulated pharmacy — not to research-grade material.